Skip to content
    ILMN
    Earnings call· Sep 2025(Q3 FY25)

    ILLUMINA, INC. ILMN

    Oct 30, 2025 Source

    Executive summary

    Illumina Q3 FY25 — Strong Clinical Growth and NovaSeq X Transition

    Illumina delivered a strong Q3 FY25, exceeding revenue and EPS guidance, driven by robust clinical growth and successful NovaSeq X adoption. The company returned to growth ex-China, expanded operating margins, and raised its full-year outlook despite ongoing challenges in China and muted research funding. Management remains focused on disciplined execution and multiomics expansion to achieve long-term financial targets.

    Highlights

    5

    • Total revenue of $1.08 billion, above guidance range.

    • Revenue ex China grew approximately 2% year-over-year.

    • Non-GAAP operating margin expanded 190 basis points to 24.5%.

    • Non-GAAP diluted EPS of $1.34, up 18% year-over-year and above guidance.

    • NovaSeq X transition achieved 78% of high-throughput volumes and 51% of high-throughput revenue on X platform in Q3.

    Concerns

    4

    • Greater China revenue was $52 million, with instruments business down approximately 54% due to export restrictions.

    • Research and applied consumables sales declined high single digits outside of China due reflecting funding uncertainty and pricing dynamics.

    • Sequencing service and other revenue was down approximately 3% year-over-year, below expectations.

    • Tariffs impacted gross margins by roughly 220 basis points on a year-over-year basis.

    Guidance & targets

    14
    CategoryTargetConfidence
    Full-year 2025 Greater China revenue
    approximately $220 million
    medium materiality
    High
    Full-year 2025 Rest of the World revenue growth (constant currency)
    0.5% to 1.5%
    high materiality
    High
    Full-year 2025 total Illumina constant currency revenue decline
    minus 0.5% to minus 1.5%
    high materiality
    High
    Full-year 2025 total Illumina reported revenue
    $4.27 billion to $4.31 billion
    high materiality
    High
    Full-year 2025 sequencing consumables growth (Rest of World ex China)
    2.5% to 3%
    medium materiality
    High
    Full-year 2025 sequencing instruments decline
    minus 6% to minus 4%
    medium materiality
    High
    Full-year 2025 non-GAAP operating margin
    22.75% to 23%
    high materiality
    High
    Full-year 2025 non-GAAP tax rate
    approximately 20.5%
    medium materiality
    High
    Full-year 2025 weighted average shares outstanding
    roughly 156 million shares
    low materiality
    High
    Full-year 2025 non-GAAP diluted EPS
    $4.65 to $4.75
    high materiality
    High
    Q4 2025 year-over-year revenue growth (Rest of the World ex China)
    step up to 4%
    medium materiality
    High
    Q4 2025 China revenue contribution
    $33 million
    medium materiality
    High
    Long-term revenue growth
    high single-digit
    high materiality
    High
    Long-term non-GAAP operating margins
    20%
    high materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Total Illumina
    Revenue exceeded the top end of our guidance range on both a constant currency and reported basis.
    		$1.08 billionroughly flat——
    Rest of the World (ex China)
    Business outside of China returned to growth, an important milestone towards long-term goals.
    		—approximately 2%——
    Greater China
    Revenue came in ahead of guidance despite ongoing export restrictions. Instruments business was down approximately 54% due to restrictions on exportation of instruments into China.
    		$52 million———

    Operational metrics

    29
    Non-GAAP operating margin
    24.5%expanded 190 basis points year-over-year
    Q3 FY25

    Reflecting strong year-over-year expansion and above guidance.

    Non-GAAP diluted EPS
    $1.34grew 18% year-over-year
    Q3 FY25

    Above guidance range.

    Sequencing consumables revenue
    $747 millionroughly flat year-over-year
    Q3 FY25

    On both reported and constant currency basis.

    Sequencing consumables revenue growth
    about 3%year-over-year
    Q3 FY25

    On both reported and constant currency basis.

    High-throughput volumes on X platform
    78%
    Q3 FY25

    Achieved the milestone for high-throughput gigabases shipped.

    High-throughput revenue on X platform
    51%
    Q3 FY25

    Achieved the milestone for high-throughput revenue.

    Research volumes on X platform
    91%
    Q3 FY25

    Of high throughput volumes.

    Clinical volumes on X platform
    64%
    Q3 FY25

    Of volumes in the quarter.

    Clinical consumables revenue growth
    double-digit
    Q3 FY25

    Driven by broader adoption of comprehensive genomic profiling and growing use of sequencing-intensive applications like MRD.

    Research and applied consumables sales decline
    high single digits
    Q3 FY25

    Reflecting continued funding uncertainty and pricing dynamics tied to the X transition.

    Total sequencing GB output growth
    more than 30%year-over-year
    Q3 FY25

    Driven by robust strength in clinical, but a more muted growth from research customers.

    Sequencing instruments revenue
    $107 millionup approximately 3% year-over-year
    Q3 FY25

    Driven by the broad adoption of the MiSeq 100 in the low-throughput space.

    Sequencing instruments revenue growth
    6%year-over-year
    Q3 FY25

    On both a reported and constant currency basis.

    NovaSeq X placements
    over 55
    Q3 FY25

    In line with the goal of 50 to 60 placements per quarter.

    NovaSeq X placements to clinical customers
    over 50%
    Q3 FY25

    In line with recent trends.

    Sequencing service and other revenue
    $147 milliondown approximately 3% year-over-year
    Q3 FY25

    Below expectations, mainly due to the timing of certain strategic partnership revenues.

    Non-GAAP gross margin
    69.2%
    Q3 FY25

    Tariffs impacted gross margins by roughly 220 basis points on a year-over-year basis.

    Tariff impact on gross margin
    220year-over-year
    Q3 FY25

    Impacted gross margins.

    Non-GAAP operating expenses
    $484 milliondown approximately 6% or $33 million year-over-year
    Q3 FY25

    Reflecting results of multiyear cost reduction programs while prioritizing key growth investments.

    Non-GAAP operating profit growth
    approximately 9%year-over-year
    Q3 FY25

    Reflecting increased operating leverage from the improved cost structure.

    Non-GAAP other expense (net interest expense)
    $13 million
    Q3 FY25

    Largely comprised of net interest expense.

    Non-GAAP tax rate
    18.6%
    Q3 FY25

    Slightly higher than expectations.

    Average diluted shares
    $154 millionroughly $3 million lower than last quarter
    Q3 FY25

    Driven by an increased level of share repurchases, net of dilution from employee equity awards.

    Cash flow provided by operations
    $284 million
    Q3 FY25

    Robust cash flow.

    Capital expenditures
    $31 million
    Q3 FY25
    Share repurchases
    $120 million
    Q3 FY25
    Remaining share repurchase authorization
    $684 million
    Q3 FY25

    Intends to continue to repurchase shares opportunistically.

    Cash, cash equivalents and short-term investments
    $1.28 billion
    Q3 FY25

    At quarter end.

    Gross leverage
    1.6x
    Q3 FY25

    Industry KPIs

    8
    MetricValueDetails
    Revenue EPS guidanceFY25 revenue: $4.27B-$4.31B (reported); FY25 non-GAAP EPS: $4.65-$4.75USD
    China revenue exposure$52 millionUSD
    Pricing price realization—
    Diagnostics testing demand—
    M a contribution synergies—
    Segment organic revenue growthapproximately 2%%
    Instruments vs consumables services mixConsumables: $747M; Instruments: $107M; Services & Other: $147MUSD
    Organic core revenue growth by end marketapproximately 2%%

    Product announcements

    3
    ProductTypeDetails
    Illumina Protein Preplaunch
    5-base solutionlaunch
    BioInsightlaunch

    Deals & partnerships

    1
    Standard BioToolsAcquisition of SomaLogic and other specified assets.

    Entered into a definitive agreement with Standard BioTools to acquire SomaLogic and other specified assets. Working with regulatory authorities to obtain clearance.

    Risks & headwinds

    4
    Export restrictions in Chinaongoing

    Greater China instruments business down approximately 54% year-over-year in Q3.

    Mitigation: Received approval to serve OEM partners through local manufacturing of select instruments in China; remaining in dialogue with relevant agencies for a long-term resolution.

    Funding uncertainty and pricing dynamics in research and applied marketsongoing, expected to remain muted into 2026

    Consumables sales declined high single digits outside of China in Q3.

    Mitigation: Engaging closely with customers to sustain their work; pricing headwinds easing as NovaSeq X transition completes; hopeful for stabilization of NIH grants and increased predictability of funding.

    Tariff impact on gross marginsongoing

    Roughly 220 basis points impact on gross margins year-over-year in Q3.

    Mitigation: Working towards mitigating the impact.

    Timing of certain strategic partnership revenuesQ3 FY25

    Sequencing service and other revenue down approximately 3% year-over-year, below expectations.

    Mitigation: Not explicitly stated, but implies a temporary timing issue rather than a structural problem.

    What to watch in Q4 FY25

    5

    Clinical NovaSeq X transition progress

    Next quarter (Q4 FY25) and beyond
    Current64% of clinical volumes on X in Q3 FY25
    TargetContinued acceleration of clinical X transition

    Why it matters

    Critical for sustained clinical revenue growth and easing pricing headwinds, as clinical adoption drives volume and revenue acceleration.

    The clinical X transition has progressed to roughly 64% of volumes in the quarter.

    Q&A highlights

    5

    What is the outlook for China in 2026, and how does Illumina view the competitive landscape, especially after ASHG?

    Management is pleased with China's Q3 performance and local manufacturing approval but states it's too early for 2026 guidance, taking it quarter-by-quarter. They acknowledge competition but emphasize Illumina's differentiation on multiple dimensions like data quality, workflow, and end-to-end cost.

    “We are taking this right now, quarter-by-quarter. It will be too early for us to go in and give you a view on '26.”

    asked by Puneet Souda · answered by Jacob Thaysen

    2 min read6 chapters

    Detailed Narrative

    01

    NovaSeq X Transition Success

    Illumina successfully transitioned 78% of high-throughput gigabase volumes and 51% of high-throughput revenue to the NovaSeq X platform in Q3, exceeding year-end goals. This rapid adoption, particularly in clinical markets, demonstrates strong sequencing demand elasticity and positions the company for sustained growth as pricing headwinds ease. The NovaSeq X is proving to be an ideal solution, delivering higher throughput with trusted accuracy and workflow.

    02

    Clinical Market Acceleration

    Clinical sequencing consumables revenue grew at a high single-digit rate year-over-year, driven by new assay approvals, positive reimbursement decisions, and increasing demand for sequencing-intensive tests like MRD. The company observed that for customers fully transitioned to NovaSeq X, volume offset price in year one, with both revenue and volume accelerating in year two, supporting continued growth in 2026 and beyond.

    03

    Multiomics Expansion

    The company launched Illumina Protein Prep in Q3, a co-developed proteomics assay leveraging NGS for protein analysis, and expanded its multiomics portfolio with a 5-base solution at ASHG. The 5-base solution integrates library prep and software to simultaneously read genetic variances and DNA methylation, delivering accurate single-base resolution while reducing complexity and cost. These initiatives aim to shift focus from cost per gigabase to delivering high-quality biological insights.

    04

    BioInsight Initiative

    Illumina introduced BioInsight, a new business designed to accelerate the use of genomic and multiomics data in drug discovery and research. This platform consolidates population sequencing programs, data partnerships, and software/AI capabilities, creating a strategic avenue for collaboration with governments, biopharma, and research institutions. BioInsight is expected to generate and interpret data at greater scale, capturing new opportunities and supporting long-term financial targets.

    05

    China Operations and Export Restrictions

    Despite ongoing export restrictions, China revenue exceeded guidance, with the company receiving approval to serve OEM partners through local manufacturing of select instruments. While a long-term resolution is still pending, management remains in dialogue with relevant agencies. The resilience of the China team and continued customer demand for Illumina's technology were highlighted as positive factors in a challenging environment.

    06

    Disciplined Execution and Margin Expansion

    Illumina achieved non-GAAP operating margin expansion of 190 basis points to 24.5% in Q3, reflecting successful multi-year cost reduction programs and increased operating leverage. Non-GAAP operating expenses were down approximately 6% year-over-year. Management expressed confidence in further margin expansion and achieving its long-term target of 20% non-GAAP operating margins by 2027, driven by continued cost actions and stronger operating leverage.

    AI-generated summary of the company’s earnings call. Not investment advice.